Publications by authors named "C Charuvastra"
Article Synopsis
- The study examines the effectiveness of buprenorphine treatment for opioid dependence across three different settings: an opioid treatment program (OTP), a group counseling program using the Matrix Model, and a private psychiatrist clinic.
- Participants received a year-long buprenorphine treatment, with varied treatment visit schedules, and outcomes were measured based on opioid use, retention in treatment, and participation in counseling.
- Results indicated that while opioid use was consistent across sites, retention rates differed significantly depending on the treatment setting, pointing to the effectiveness of the environment in supporting participant engagement.
Aims: To evaluate the efficacy and safety of the PROMETA™ Protocol for treating methamphetamine dependence.
Design: A double-blind, placebo-controlled 108-day study with random assignment to one of two study conditions: active medication with flumazenil (2 mg infusions on days 1, 2, 3, 22, 23), gabapentin (1200 mg to day 40) and hydroxazine (50 mg to day 10) versus placebo medication (with active hydroxazine only).
Setting: Three substance abuse treatment clinics: two in-patient, one out-patient.
Although buprenorphine is approved for use in the outpatient treatment of opioid addiction in 2 tablet formulations, a monoproduct containing buprenorphine only (Subutex) and a buprenorphine/naloxone combination product (Suboxone), much of the clinical data that support the approval by the U.S. Food and Drug Administration were generated by using a sublingual liquid.
View Article and Find Full Text PDFA screening trial of amantadine as a medication for cocaine dependence.
Drug Alcohol Depend
May 2002
This screening trial evaluated whether amantadine hydrochloride (100 mg bid) demonstrated sufficient clinical efficacy compared to placebo to recommend development as a pharmacotherapy for cocaine dependence. Participants were randomized to amantadine (n=34) or placebo (n=35) conditions in a 16-week, placebo-controlled, double blind trial with three times per week group counseling. Amantadine-treated participants were retained significantly longer than placebo.
View Article and Find Full Text PDFAims: To evaluate the safety and efficacy of an 8 mg/day sublingual dose of buprenorphine in the maintenance treatment of heroin addicts by comparison with a 1 mg/day dose over a 16-week treatment period. As a secondary objective, outcomes were determined concurrently for patients treated with two other dose levels.
Design: Patients were randomized to four dosage groups and treated double-blind.